The Impact of Tamoxifen and Aromatase Inhibitors on Platelet Proteins

Platelet Modulation in the Control of Angiogenesis: The Impact of Tamoxifen and Aromatase Inhibitors on Platelet Activation and Angiogenic Proteins

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01341171

Enrollment

Registered

2011-04-25

Start date

2009-08-31

Completion date

2018-10-31

Last updated

2020-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

tamoxifen, aromatase inhibitors, breast cancer, platelets

Brief summary

Single phlebotomy study involving women receiving tamoxifen or aromatase inhibitor therapy.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

OTHER

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* women routinely taking tamoxifen or aromatase inhibitor therapy as prescribed by their oncologist

Exclusion criteria

* Use of heparin, warfarin

Design outcomes

Primary

Measure	Time frame
Angiogenic Protein levels	following 6 months of therapy

Countries

United States

Outcome results